China Medical System (HKG:0867) secured National Medical Products Administration of China's approval for its new drug application for ruxolitinib phosphate cream as treatment for vitiligo, a Wednesday filing with the Hong Kong bourse said.
Vitiligo is a chronic autoimmune disease that causes depigmentation of the skin.
The pharmaceutical innovation and commercialization company's shares fell over 4% on Wednesday's close.
Price (HKD): $7.98, Change: $-0.36, Percent Change: -4.32%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。